Association Among Serum Fetuin-A Level, Coronary Artery Calcification, and Bone Mineral Densitometry in Maintenance Hemodialysis Patients
Corresponding Author
Alper Kirkpantur
Departments of Internal Medicine, Nephrology Unit,
Dr. Alper Kirkpantur, 23. Sokak Balkas Apt. No:3/13, Bahcelievler-Cankaya, 06500, Ankara, Turkey. E-mail: [email protected]; [email protected]Search for more papers by this authorBulent Altun
Departments of Internal Medicine, Nephrology Unit,
Search for more papers by this authorMustafa Arici
Departments of Internal Medicine, Nephrology Unit,
Search for more papers by this authorSerafettin Kirazli
Hematology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Search for more papers by this authorCetin Turgan
Departments of Internal Medicine, Nephrology Unit,
Search for more papers by this authorCorresponding Author
Alper Kirkpantur
Departments of Internal Medicine, Nephrology Unit,
Dr. Alper Kirkpantur, 23. Sokak Balkas Apt. No:3/13, Bahcelievler-Cankaya, 06500, Ankara, Turkey. E-mail: [email protected]; [email protected]Search for more papers by this authorBulent Altun
Departments of Internal Medicine, Nephrology Unit,
Search for more papers by this authorMustafa Arici
Departments of Internal Medicine, Nephrology Unit,
Search for more papers by this authorSerafettin Kirazli
Hematology, Hacettepe University Faculty of Medicine, Ankara, Turkey
Search for more papers by this authorCetin Turgan
Departments of Internal Medicine, Nephrology Unit,
Search for more papers by this authorAbstract
Patients with end-stage renal disease have a very high prevalance and extent of arterial calcification. A number of studies suggest that similar pathophysiologic mechanisms are responsible for development and progression of calcification of atherosclerotic plaque and bone formation. Fetuin-A is a potent calcification inhibitor and is expressed in bone, with not-yet well-defined functions. The aim of this study was to investigate the relation between bone mineral densitometry parameters, coronary artery calcification, and serum fetuin-A levels. In a cross-sectional design, we included 72 maintenance hemodialysis (HD) patients and 30 age- and gender- matched healthy controls. Serum fetuin-A levels were studied both in maintenance HD patients and healthy controls. Maintenance HD patients had radius, hip, and lumbar spine bone mineral density (BMD) assessed by dual-energy X-ray absorptiometry and coronary artery calcification score (CACS) measured by electron-beam computed tomography. The associations between site-specific BMD parameters, CACS, and serum fetuin-A levels were studied in maintenance HD patients. CACS, mass, and volume of plaques in coronary arteries were significantly higher in patients with a T-score below −2.5 than above in the proximal region of the radius, neck and trochanter of the femur, and the lumbar spine. Mean serum fetuin-A concentration was 0.636 ± 0.118 g/L in maintenance HD patients and it was less than healthy controls (0.829 ± 0.100 g/L, P < 0.0001). CACS, mass, and volume of plaques in coronary arteries correlated significantly with the serum fetuin-A levels. Moreover, significant positive correlations were shown between the serum fetuin-A levels, BMD values, and T-scores of proximal radius, neck, and trochanter of the femur, but not with the lumbar spine. The present study demonstrates an association between serum fetuin-A levels, coronary artery calcification, and bone mineral densities—except for the lumbar spine, in maintenance HD patients. However, the results should be interpreted with caution because of the cross-sectional design of the study.
REFERENCES
- 1 Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients: a link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39: 695–701.
- 2 Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394–401.
- 3 Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478–83.
- 4 Chertow GM, Burke SK, Raggi P, for the Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245–52.
- 5 Blacher J, Guérin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001; 38: 938–42.
- 6 Cannata-Andia JB, Rodriguez-Garcia M, Carrillo-Lopez N, Naves-Diaz M, Diaz-Lopez B. Vascular calcifications: pathogenesis, management, and impact on clinical outcomes. J Am Soc Nephrol 2006; 17: S267–73.
- 7 Schäfer C, Heiss A, Schwarz A, et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003; 112: 357–66.
- 8 Fontaine MA, Albert A, Dubois B, Saint-Remy A, Rorive G. Fracture and bone mineral density in hemodialysis patients. Clin Nephrol 2000; 54: 218–26.
- 9 Schulz E, Arfai K, Liu X, Sayre J, Gilsanz V. Aortic calcification and the risk of osteoporosis and fractures. J Clin Endocrinol Metab 2004; 89: 4246–53.
- 10 Dziegielewska KM, Brown WM. Fetuin. Heidelberg: Springer-Verlag, 1995.
- 11 Ketteler M, Bongartz P, Westenfeld R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 2003; 361: 827–33.
- 12 Triffitt JT, Gebauer U, Ashton BA, Owen ME, Reynolds JJ. Origin of plasma alpha2HS-glycoprotein and its accumulation in bone. Nature 1976; 262: 226–7.
- 13 Keeley KW, Sitarz EE. Identification and quantitation of alpha 2-HS-glycoprotein in the mineralized matrix of calcified plaques of atherosclerotic human aorta. Atherosclerosis 1985; 55: 63–9.
- 14 Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996; 271: 20789–96.
- 15 Yang F, Schwartz Z, Swain LD, Lee CC, Bowman BH, Boyan BD. Alpha 2-HS-glycoprotein: expression in chondrocytes and augmentation of alkaline phosphatase and phospholipase A2 activity. Bone 1991; 12: 7–15.
- 16 Demetriou M, Binkert C, Sukhu B, Tenenbaum HC, Dennis JW. Fetuin/α2-HS glycoprotein is a transforming growth factor-β type II receptor mimic and cytokine antagonist. J Biol Chem 1996; 271: 12755–61.
- 17 Szweras M, Liu D, Partridge EA, et al. α2-HS Glycoprotein/fetuin, a transforming growth factor-β/bone morphogenetic protein antagonist, regulates postnatal bone growth and remodeling. Biol Chem 2002; 22: 19991–7.
- 18 Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 1996; 7: 728–36.
- 19 Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993; 4: 1205–13.
- 20 Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoproteins cholesterol in plasma without use of the ultracentrifuge. Clin Chem 1972; 18: 499–502.
- 21 Chobanian AV, Bakris GL, Black HR, et al. Joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560–72.
- 22 Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15: 827–32.
- 23 Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929–36.
- 24 Taal MW, Masud T, Green D, Cassidy MJD. Risk factors for reduced bone density in haemodialysis patients. Nephrol Dial Transplant 1999; 14: 1922–8.
- 25 Nakashima A, Yorioka N, Tanji C, et al. Bone mineral density may be related to atherosclerosis in hemodialysis patients. Osteoporos Int 2003; 14: 369–73.
- 26 Rodriguez-Garcia M, Naves Diaz M, Cannata Andia JB. Bone metabolism, vascular calcifications and mortality: associations beyond mere coincidence. J Nephrol 2005; 18: 458–63.
- 27 Rodriguez-Garcia M, Gomez Alonso C, Naves Diaz M, et al. Vascular calcification, bone mass, vertebral fractures andmortality in hemodialysis patients. J Am Soc Nephrol 2004; 15: 175A. [Abstract.
- 28 Price PA, Roublick AM, Williamson MK. Artery calcification in uremic rats is increased by a low protein diet and prevented by treatment with ibandronate. Kidney Int 2006; 70: 1577–83.
- 29 Davies MR, Lund RJ, Mathew S, Hruska KA. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J Am Soc Nephrol 2005; 16: 917–28.
- 30 Stompór T, Pasowicz M, Sulłowicz W, et al. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis 2003; 41: 203–11.
- 31 Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant 2006; 21: 1915–20.
- 32 Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: impact of variations in the gene encoding fetuin. Kidney Int 2005; 67: 2383–92.
- 33 Hermans MM, Brandenburg V, Ketteler M, et al. Study on the relationship of serum fetuin-A concentration with aortic stiffness in patients on dialysis. Nephrol Dial Transplant 2006; 21: 1293–9.
- 34 Ganesan K, Teklehaimanot S, Tran TH, Asuncion M, Norris K. Relationship of C-reactive protein and bone mineral density in community-dwelling elderly females. J Natl Med Assoc 2005; 97: 329–33.
- 35 Malluche H, Monier-Faugere CM. Risk of adynamic bone disease in dialyzed patients. Kidney Int 1992; 42(Suppl. 38): S62–7.
- 36 Coen G, Manni M, Agnoli A, et al. Cardiac calcifications: fetuin-A and other risk factors in hemodialysis patients. ASAIO J 2006; 52: 150–6.
- 37 National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl. 3): S1–201.
- 38 Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease. Kidney Int 2005; 67: 2295–304.
- 39 Moe SM, Chen XN, O'Neill KD, et al. Fetuin-A and matrix gla protein (MGP) are important inhibitors of vascular calcification in CKD. J Am Soc Nephrol 2003; 14: 692. [Abstract.
- 40 Mehrotra R, Westenfeld R, Christenson P, et al. Serum fetuin-A in non-dialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int 2005; 67: 1070–7.
- 41 Binkert C, Demetriou M, Sukhu B, Szweras M, Tenenbaum HC, Dennis JW. Regulation of osteogenesis by fetuin. J Biol Chem 1999; 274: 28514–20.
- 42 Reynolds JL, Skepper JN, McNair R, et al. Multifunctional roles for serum protein fetuin-A in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol 2005; 16: 2920–30.
- 43 Adams CS, Mansfield K, Perlot RL, Shapiro IM. Matrix regulation of skeletal cell apoptosis. Role of calcium and phosphate ions. J Biol Chem 2001; 276: 20316–22.
- 44 Coen G, Ballanti P, Balducci A, et al. Renal osteodystrophy: α-heremans schmid glycoprotein/fetuin-A, matrix GLA protein serum levels, and bone histomorphometry. Am J Kidney Dis 2006; 48: 106–13.
- 45 Martin KJ, Fukagawa M, Malluche HH. Diagnosis of bone and mineral disorders. In: K Olgaard, ed. Clinical Guide to Bone and Mineral Metabolism in CKD, 1st Edition. New York: National Kidney Foundation, 2006; 45–73.
- 46 Barnas U, Schmidt A, Seidl G, Kaider A, Pietschmann P, Mayer G. A comparison of quantitative computed tomography and dual X-ray absorptiometry for evaluation of bone mineral density in patients on chronic hemodialysis. Am J Kidney Dis 2001; 37: 1247–52.
- 47 Johnson DW, McIntyre HD, Brown A. The role of DEXA bone densitometry in evaluating renal osteodystrophy in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1996; 16: 34–40.
- 48 Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Associations between vascular calcification, arterial stiffness and bone mineral density in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 586–93.
- 49 Piraino B, Chen T, Cooperstein L, Segre G, Puschett J. Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clin Nephrol 1998; 30: 57–62.
- 50 Moe SM, Yu BO, Sprague SM. Maintenance of bone mass in patients receiving dialytic therapy. Am J Kidney Dis 1993; 22: 300–7.
- 51 Eknoyan G, Levin A, Levin NW, National Kidney Foundation. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(Suppl. 3): 1–201.
- 52 Meunier P, Courpron P, Giroux JM, Edouard C, Bernard J, Vignon G. Bone histomorphometry as applied to research on osteoporosis and to the diagnosis of “hyperosteoidosis states. Calcif Tissue Res 1976; 21: 354–60.
Citing Literature
